Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clinical Groups Call For 'Me-Too' Pathway For Infectious Disease LDT Approvals

This article was originally published in The Gray Sheet

Executive Summary

A group of infectious disease and clinical virology societies are asking FDA to establish an alternative under the agency's proposed lab-developed test framework for infectious disease test services. Clinical laboratories should be able to use commercial high-risk tests as predicates for ID LDTs so they won't have to go through the costly PMA submissions process.

Advertisement

Related Content

FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions

Topics

Advertisement
UsernamePublicRestriction

Register